Rigel Pharmaceuticals (RIGL) Total Liabilities (2010 - 2026)

Rigel Pharmaceuticals' Total Liabilities history runs 17 years deep, the most recent figure standing at $104.7 million for Q1 2026.

• In Q1 2026, Total Liabilities fell 33.48% year-over-year to $104.7 million; the TTM figure through Mar 2026 stood at $104.7 million (down 33.48% YoY), while the FY2025 annual figure was $122.1 million, down 24.01% from the prior year.
• Total Liabilities was $104.7 million for Q1 2026 at Rigel Pharmaceuticals, down from $122.1 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $160.7 million in Q4 2024 to a low of $104.7 million in Q1 2026.
• Historically, Total Liabilities has averaged $141.7 million across 5 years, with a median of $145.9 million in 2023.
• The sharpest annual moves came in 2023 and 2026: Total Liabilities climbed 10.27% in 2023, then sank 33.48% in 2026.
• A 5-year view of Total Liabilities shows it stood at $147.9 million in 2022, then decreased by 1.37% to $145.9 million in 2023, then increased by 10.16% to $160.7 million in 2024, then decreased by 24.01% to $122.1 million in 2025, then decreased by 14.25% to $104.7 million in 2026.
• The last three Total Liabilities figures came in at $104.7 million (Q1 2026), $122.1 million (Q4 2025), and $124.9 million (Q3 2025), per Business Quant data.